<!DOCTYPE html>
<html lang="" xml:lang="">
  <head>
    <title>SARS-CoV-2 Pandemic 2019-now</title>
    <meta charset="utf-8" />
    <meta name="author" content="Elena Dudukina, Raquel Raquel Avelar" />
    <meta name="date" content="2020-04-08" />
    <link rel="stylesheet" href="xaringan-themer.css" type="text/css" />
  </head>
  <body>
    <textarea id="source">
class: center, middle, inverse, title-slide

# SARS-CoV-2 Pandemic 2019-now
## Introduction to the little known
### Elena Dudukina, Raquel Raquel Avelar
### 2020-04-08

---





# Key definitions
- Attack rate
  - The proportion of the population which contracts the disease from the population at risk

- Case-fatality risk (CFR)
  - The probability that a person dies from an infection given that they are a case

- Infection-fatality risk (IFR)
  - Defines a case as a person who has shown evidence of infection, either by clinical detection of the pathogen or by seroconversion or other immune response
  
- Basic reproductive number **R0** (often pronounced _"R naught"_)
  - The **average number of secondary cases** of an infection that occur **in a completely
susceptible population following a single infectious case**

.footnote[[Lipsitch, 2015](https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003846); case-fatality risk and infection-fatality risk are sometimes referred to as "rates".]

---
# Basic Reproductive Number
.pull-left[

  _How many other people one contagious individual will infect in non-immune population?_
  
  - Mathematical modeling of transmission within populations
  ]

.right[
![](r0-covid19.png)
]

.footnote[
[Vox, 2020](https://www.vox.com/science-and-health/2020/4/2/21197617/coronavirus-pandemic-covid-19-death-rate-transmission-risk-factors-lockdowns-social-distancing)

[NEJM, 2020](https://www.nejm.org/doi/full/10.1056/NEJMoa2001316)]

---
 # Contemporary epidemics history

- **2002-2004** **SARS** (SARS-CoV virus)
    - R0: 2.0 to 4.0 ([WHO, 2003](https://www.who.int/csr/sars/en/WHOconsensus.pdf))
    - 8096 cases
    - 774 deaths in 32 countries **→** case fatality rate 9.6% ([WHO, 2004](https://www.who.int/csr/sars/country/table2004_04_21/en/))
    - Vaccine inducing neutrolizing antibodies now available ([Chien-Te Tseng, 2012](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335060/))

--

- **2009** 2nd pandemic caused by **H1N1 influenza virus** (H1N1/09, or "Swine flue")
    - R0: 1.5 (1.3 to 1.7)
    -	0.7–1.4 **billion** estimated infected worldwide
    -	151,700–575,400 estimated deaths worldwide
    -	Vaccine now available
    
---
- **2012-present** **MERS** (MERS-CoV)
    - R0 &lt;1 [(WHO, 2019)](https://apps.who.int/iris/bitstream/handle/10665/326126/WHO-MERS-RA-19.1-eng.pdf?ua=1)
      - Heterogenous R0: 1.0-5.7 at the start of the outbreak → &lt; 1.0 [(Bernard-Stoecklin, 2019)](https://www.nature.com/articles/s41598-019-43586-9)
    - 2012-2016: 1841 laboratory confirmed cases → 80% in the Kingdom of Saudi Arabia
    -	35% (n=652) died
--

-	**2014-2016 Ebola**
    - 28,542 cases
    -	11,299 deaths
    -	CFR was 40%

---

 # Emerging Infectious Diseases
**Identification of infectious agents and diseases that were not recognized before**

## Infection states

- Progression-Related

State of Infection | Definition
 -------------|--------------------------------------
Colonization | Transient colonization tissue invasion
Subclinical infection | Agent is present in host tissues without signs, symptoms, or laboratory evidence of tissue damage
Latency | Infection in which the agent has invaded the host and is in a nonreplicating, noninfectious, but viable state
Disease | Agent is replicating in host tissues with signs, symptoms, or laboratory evidence of tissue damage
Cure | Agent has been eliminated from host tissue (may persist on surface)

---
# Infection states

- Transmission-Related

State of Infection | Definition
 --------|---------|---------
Preinfectious | Host is infected but has not become infectious
Infectious | Host is capable of transmitting agent to others
Postinfectious | Host is no longer capable of transmission

.footnote[Rothman KJ, Modern Epidemiology, 3rd Edition]

---
# Modeling infectious diseases spread
- **Aims**
  - Prediction
  - Consequences of intervention ("causal" flavour and counterfactual reasoning)
- **Models**
  - **Deterministic compartmental models (DCMs)**
      - SIR (Susceptible → Infectious → Recovered)
      - SIRS (Susceptible → Infectious → Recovered → Susceptible)
      - SEIR (Susceptible → Exposed → Infectious → Recovered)
      - Modifications accomodating other compartments to model post-infection immunity, vaccination, etc.
      - Straightforward, transparent, does not always reflect real-life complexities
  
  _Simulating individuals not the population groups_
  - **Agent-based models (ABMs)**
  - **Network models**

- Calibration, Validation, Sensitivity analyses

.left[
[Dr. Samuel Jenness, 2020](https://scholarblogs.emory.edu/epi/2020/04/05/modeling-covid-19/?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=modeling-covid-19); [Imperial College London](https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-03-30-COVID19-Report-13.pdf)
]

---
# Coronavirus disease (COVID-19) outbreak

- **SARS-CoV-2**
- β-coronavirus (other two known β-CoVs are SARS-CoV and MERS-CoV)
- Origin: bats via unknown intermediate hosts to infect humans
- Uses angiotensin-converting enzyme 2 (ACE2), the same receptor as SARS-CoV, to infect humans
- Incubation period
    - Median 5.1 days (4.5 to 5.8 days)
    - 97.5% of those who develop symptoms will do so within 11.5 days ([mainland China data](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081172))
    - China CDC: 10-14 days
    - USA CDC: [2-14 days](https://www.cdc.gov/coronavirus/2019-ncov/about/symptoms.html)
- Period of infectivity: 90% negative viral RNA tests on nasopharyngeal swabs by 10 days after the onset of symptoms ([Liu, 2020](https://www.thelancet.com/action/showPdf?pii=S1473-3099%2820%2930232-2))
- Immunity: preliminary data showing that neutralizing antibodies ([Kai-Wang To, 2020](https://www.thelancet.com/action/showPdf?pii=S1473-3099%2820%2930196-1); [Ju, 2020](https://www.biorxiv.org/content/10.1101/2020.03.21.990770v1.full.pdf))

.right[![:scale 30%](SARS CoV2.jfif)]

---
# March 2020: recap
.center[![](covid19-happening.png)]

.footnote[[Imperial College London, R-13](https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-03-30-COVID19-Report-13.pdf)]
---
# Testing for COVID-19
- Different testing capacity/kits
- Different ways of recording/releasing/sharing data

- Probability of being tested is not independent of disease severity and of the outcome

- RT-PCR:
    - Tests are not perfect
      - Analytical sensitivity 95%
        - Positive (COVID-19_N_P) – positive for all targets detected (Ct &lt; 40)
      - Analytical Specificity: no cross-reactivity [(FDA, 2020)](https://www.fda.gov/media/136151/download)
      
- No reliable data on comparative accuracy of oropharyngeal vs nasopharyngeal swabs for diagnosis of COVID-19 [(The Centre for Evidence-Based Medicine, Oxford University)](https://www.cebm.net/covid-19/comparative-accuracy-of-oropharyngeal-and-nasopharyngeal-swabs-for-diagnosis-of-covid-19/)

---
**Total number of tests for COVID-19**
&lt;iframe src="https://ourworldindata.org/grapher/full-list-total-tests-for-covid-19" style="width: 100%; height: 550px; border: 0px none;"&gt;&lt;/iframe&gt;

---
** Tests per 1 million population**
&lt;iframe src="https://ourworldindata.org/grapher/full-list-cumulative-total-tests-per-million" style="width: 100%; height: 550px; border: 0px none;"&gt;&lt;/iframe&gt;

---
**Number of registrered/confirmed COVID-19 cases**

&lt;iframe src="https://ourworldindata.org/grapher/covid-confirmed-cases-since-100th-case" style="width: 100%; height: 550px; border: 0px none;"&gt;&lt;/iframe&gt;

---
**Number of registered/confirmed COVID-19 cases and case-fatality rates**

&lt;iframe src="https://ourworldindata.org/grapher/covid-19-total-confirmed-cases-vs-total-confirmed-deaths?time=0..76" style="width: 100%; height: 550px; border: 0px none;"&gt;&lt;/iframe&gt;

---
**Case-fatality rates among registrered/confirmed COVID-19 cases**

&lt;iframe src="https://ourworldindata.org/grapher/coronavirus-cfr?year=17&amp;time=-2..76" style="width: 100%; height: 550px; border: 0px none;"&gt;&lt;/iframe&gt;
 
---
![:scale 75%](COVID-CFR-by-age.png)
---
**Beware of bias when interpreting case-fatality rate**
- The data we use to estimate the CFR are often gathered for other purposes
- Challenging &amp; constantly changing circumstances
- Preferential testing and counting of severe cases → overestimation
- At any point during ongoing epidemic we haven't yet observed disease outcomes for everyone → underestimation
- Delayed reporting: outcomes observed now are reported later
- Forward contact tracing → pre-symptomatic individuals → less prone to bias CFR estimates

- Comparison of CFR across groups
  - E.g., hospitalized vs non-hospitalized → multiple competing biases
      - Suvivorship
      - Selection
      - Confounding

- Inference is never based on available data alone
    - Data collection + what we did not collect + what we collected + assumptions

.footnote[[Lipsitch, 2015](https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003846)]
---
# Delayed reporting

.pull-left[
&lt;blockquote class="twitter-tweet"&gt;&lt;p lang="en" dir="ltr"&gt;To summarise, I think it’s better to use the NHS England deaths data to illustrate progression of UK deaths and as a starting point for projections - taking the difference between the total daily death figures from the DHSC gives a misleading shape. 14/ &lt;a href="https://t.co/5cQwoXYyUl"&gt;pic.twitter.com/5cQwoXYyUl&lt;/a&gt;&lt;/p&gt;&amp;mdash; Matt Fletcher (@longevitymatt) &lt;a href="https://twitter.com/longevitymatt/status/1247449193536466945?ref_src=twsrc%5Etfw"&gt;April 7, 2020&lt;/a&gt;&lt;/blockquote&gt; &lt;script async src="https://platform.twitter.com/widgets.js" charset="utf-8"&gt;&lt;/script&gt;
]

.pull-right[
![](uk-delayed-deaths.jpg)
]
---
# Asymptomatic or pre-symptomatic?

.pull-left[
&lt;blockquote class="twitter-tweet"&gt;&lt;p lang="en" dir="ltr"&gt;This is a misreading of the data from China, interepreting numbers from one population as being from another. Please see attached and withdraw the manuscript immediately &lt;a href="https://t.co/JTYqMmuCdF"&gt;pic.twitter.com/JTYqMmuCdF&lt;/a&gt;&lt;/p&gt;&amp;mdash; Yaneer Bar-Yam (@yaneerbaryam) &lt;a href="https://twitter.com/yaneerbaryam/status/1246158748047073286?ref_src=twsrc%5Etfw"&gt;April 3, 2020&lt;/a&gt;&lt;/blockquote&gt; &lt;script async src="https://platform.twitter.com/widgets.js" charset="utf-8"&gt;&lt;/script&gt;
]

.pull-right[![:scale 85%](pre-symptomatic.jfif)]

---
# Risk factors for severe COVID-19 illness
.pull-left[
- Age 60+

- Comorbidities
  - Cardiovascular disease
  - Diabetes mellitus
  - Chronic lung disease
  - Hypertension
  - Cancer
  - Chronic kidney disease
  
- Sex
  - China: larger proportion of men was in deceased group than that in recovered group (73% vs 55%) [(Jian-Min Jin, 2020](https://www.medrxiv.org/content/10.1101/2020.02.23.20026864v2); [Chen, 2020)](https://www.bmj.com/content/368/bmj.m1091)
  - Italy: overall CFR of 11.4% in men vs 9.2% in women [(Epidemia COVID-19, Aggiornamento nazionale)](https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_26-marzo%202020.pdf)
]

.pull-right[
![](covid-comorbid.png)
]
---
# Treatment of COVID-19
- No specific treatment available
  - Oxygenation support for severely ill

- Clinical trials for variety of agents (antiviral, immune modulators, antibacterial, monoclonal antibodies, etc.)
  - Chloqoquine, hydroxychloroquine and azithromycin, tocilizumab, camostat mesilate, sargramostim, colchicine, imatinib, IFNβ-1a, inhaled steroids, remdesivir, oseltamivir, etc. [(EU Clinical Trial Register;](https://www.clinicaltrialsregister.eu/ctr-search/search?query=covid-19) [laegemiddelstyrelsen.dk)](https://laegemiddelstyrelsen.dk/da/nyheder/temaer/ny-coronavirus-covid-19/~/media/5B83D25935DF43A38FF823E24604AC36.ashx)
  - Mind the comparison groups and design features

- Available results
  - Lopinavir-ritonavir vs standard care showed no decrease in mortality of COVID-19 patients [(Cao, 2020)](https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=featured_coronavirus)

--

- Possible impact of SARS-CoV-2 epidemic on other ongoing clinical trials [(EMA, 2020)](https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-implications-coronavirus-disease-covid-19-methodological-aspects-ongoing-clinical_en.pdf)

- Need of high-quality evidence and responsible conduct of research
---
# Study of chloroquine + azytromycin
![](chlor-azytro.png)

---
# Points of concern
.left[
- Design
  - In essence - observational study without adjustment for the sources of bias
- "Control group" ascertainment
    - Refused consent to receive active treatment → allocated to "control group"
    - Ethically and methodologically problematic
- Loss-to-follow-up (selection bias)
    - From 26 patients in "treatment group", 6 were excluded (4 out of 6 developed severe disease/died)
    - Could make the treatment look beneficial when it isn't
- Outcome (SARS-CoV-2+/- on day 6)
  - Dichotomization of viral load
  - Day 6
      - No biologic justification
      - Missing outcome data
      - Some patients were positive on day 6 but negative on day 9; one was negative on day 6 but positive on day 8
      - PCR procedure different from the official CDC protocol
      - Clinical relevance of the end-point

[Dahly, Gates, Morris, 2020](https://zenodo.org/record/3724167#.XowsG9IzbBQ)]

---
# Ethical conduct of research

.pull-left[
&lt;blockquote class="twitter-tweet"&gt;&lt;p lang="en" dir="ltr"&gt;I asked Newsweek if they could add the link. &lt;br&gt;Here is that blog post, in case you wondered:&lt;a href="https://t.co/Ez5dnm8hoM"&gt;https://t.co/Ez5dnm8hoM&lt;/a&gt;&lt;/p&gt;&amp;mdash; Elisabeth StayingAtHome StayingAlive Bik (@MicrobiomDigest) &lt;a href="https://twitter.com/MicrobiomDigest/status/1247402645553176578?ref_src=twsrc%5Etfw"&gt;April 7, 2020&lt;/a&gt;&lt;/blockquote&gt; &lt;script async src="https://platform.twitter.com/widgets.js" charset="utf-8"&gt;&lt;/script&gt;
]

.pull-right[
- Peer-review?
- Conflict of interests

.pull-right[![](title-authors-and-received-accepted-dates-marked.png)]


.pull-left[![](editorial-board-of-the-journal.png)]
]
---

# Vaccine development
- **Time** 18 months
- **Funding**
 - Wellcome trust: raising **$8bn**[](https://wellcome.ac.uk/what-we-do/our-work/coronavirus-covid-19/investment/covid-zero?utm_source=twitter&amp;utm_medium=o-wellcome)
 - Coalition for Epidemic Preparedness Innovations (Cepi) + Novavax + University of Oxford
      - Established funding **$4.4m** and raising **$2bn**  [(Guardian, March 2002)](https://www.theguardian.com/world/2020/apr/06/when-will-coronavirus-vaccine-be-ready)
- Phase 1 Clinical Trial Of COVID-19 vaccine candidates [(WHO, March 2020)](https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1)

- Countries cannot afford "herd immunity" approach
  - 0.41% to 15% of population are infected across European countries by the end of March 2020 [(Imperial College London, R-13)](https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-03-30-COVID19-Report-13.pdf)
  &lt;blockquote class="twitter-tweet"&gt;&lt;p lang="en" dir="ltr"&gt;9/ Substituting in for R, we get:&lt;br&gt;&lt;br&gt;R&amp;lt;1 =&amp;gt; R0*(% susceptible)&amp;lt;1 =&amp;gt; %susceptible&amp;lt;1/R0&lt;br&gt;&lt;br&gt;Solving for R0 = 3, we get %susceptible&amp;lt;33.3%&lt;br&gt;&lt;br&gt;In other words, as long as more than 33% of the population is susceptible, the disease spreads&lt;/p&gt;&amp;mdash; Health &amp;quot;Physical Isolation&amp;quot; Nerd (@GidMK) &lt;a href="https://twitter.com/GidMK/status/1247328601155842051?ref_src=twsrc%5Etfw"&gt;April 7, 2020&lt;/a&gt;&lt;/blockquote&gt; &lt;script async src="https://platform.twitter.com/widgets.js" charset="utf-8"&gt;&lt;/script&gt;

---
# Global consequences
- Economics-related
  - Plummeted stock markets
  - Jobs' losses and unemployment
  - Recession

- Healthcare-related

- People's lives

- Poorest countries and communities are most affected and cannot cope alone

- "A Once-in-a-Century Pandemic?" [Bill Gates](https://www.nejm.org/doi/full/10.1056/NEJMp2003762)
  - "Governments and industry will need to come to an agreement"
---
# Thank you for attention
.center[![:scale 60%](from-home.jpg)]

---
# Useful resources
- https://ourworldindata.org/coronavirus#
- http://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-13-europe-npi-impact/
- https://twitter.com/EpiEllie
- https://twitter.com/mlipsitch
- https://twitter.com/CT_Bergstrom
    </textarea>
<style data-target="print-only">@media screen {.remark-slide-container{display:block;}.remark-slide-scaler{box-shadow:none;}}</style>
<script src="https://remarkjs.com/downloads/remark-latest.min.js"></script>
<script src="macros.js"></script>
<script>var slideshow = remark.create({
"ratio": "16:9",
"highlightStyle": "github",
"highlightLines": true,
"countIncrementalSlides": false
});
if (window.HTMLWidgets) slideshow.on('afterShowSlide', function (slide) {
  window.dispatchEvent(new Event('resize'));
});
(function(d) {
  var s = d.createElement("style"), r = d.querySelector(".remark-slide-scaler");
  if (!r) return;
  s.type = "text/css"; s.innerHTML = "@page {size: " + r.style.width + " " + r.style.height +"; }";
  d.head.appendChild(s);
})(document);

(function(d) {
  var el = d.getElementsByClassName("remark-slides-area");
  if (!el) return;
  var slide, slides = slideshow.getSlides(), els = el[0].children;
  for (var i = 1; i < slides.length; i++) {
    slide = slides[i];
    if (slide.properties.continued === "true" || slide.properties.count === "false") {
      els[i - 1].className += ' has-continuation';
    }
  }
  var s = d.createElement("style");
  s.type = "text/css"; s.innerHTML = "@media print { .has-continuation { display: none; } }";
  d.head.appendChild(s);
})(document);
// delete the temporary CSS (for displaying all slides initially) when the user
// starts to view slides
(function() {
  var deleted = false;
  slideshow.on('beforeShowSlide', function(slide) {
    if (deleted) return;
    var sheets = document.styleSheets, node;
    for (var i = 0; i < sheets.length; i++) {
      node = sheets[i].ownerNode;
      if (node.dataset["target"] !== "print-only") continue;
      node.parentNode.removeChild(node);
    }
    deleted = true;
  });
})();
(function() {
  "use strict"
  /* Replace <script> tags in slides area to make them executable
   *
   * Runs after post-processing of markdown source into slides and replaces only
   * <script>s on the last slide of continued slides using the .has-continuation
   * class added by xaringan. Finally, any <script>s in the slides area that
   * aren't executed are commented out.
   */
  var scripts = document.querySelectorAll(
    '.remark-slides-area .remark-slide-container:not(.has-continuation) script'
  );
  if (!scripts.length) return;
  for (var i = 0; i < scripts.length; i++) {
    var s = document.createElement('script');
    var code = document.createTextNode(scripts[i].textContent);
    s.appendChild(code);
    scripts[i].parentElement.replaceChild(s, scripts[i]);
  }
  var scriptsNotExecuted = document.querySelectorAll(
    '.remark-slides-area .remark-slide-container.has-continuation script'
  );
  if (!scriptsNotExecuted.length) return;
  for (var i = 0; i < scriptsNotExecuted.length; i++) {
    var comment = document.createComment(scriptsNotExecuted[i].outerHTML)
    scriptsNotExecuted[i].parentElement.replaceChild(comment, scriptsNotExecuted[i])
  }
})();
(function() {
  var links = document.getElementsByTagName('a');
  for (var i = 0; i < links.length; i++) {
    if (/^(https?:)?\/\//.test(links[i].getAttribute('href'))) {
      links[i].target = '_blank';
    }
  }
})();
// adds .remark-code-has-line-highlighted class to <pre> parent elements
// of code chunks containing highlighted lines with class .remark-code-line-highlighted
(function(d) {
  const hlines = d.querySelectorAll('.remark-code-line-highlighted');
  const preParents = [];
  const findPreParent = function(line, p = 0) {
    if (p > 1) return null; // traverse up no further than grandparent
    const el = line.parentElement;
    return el.tagName === "PRE" ? el : findPreParent(el, ++p);
  };

  for (let line of hlines) {
    let pre = findPreParent(line);
    if (pre && !preParents.includes(pre)) preParents.push(pre);
  }
  preParents.forEach(p => p.classList.add("remark-code-has-line-highlighted"));
})(document);</script>
<style>
.logo {
  background-image: url(AU.png);
  background-size: contain;
  background-repeat: no-repeat;
  position: absolute;
  top: 1em;
  right: 1em;
  width: 110px;
  height: 128px;
  z-index: 0;
}
</style>

<script>
document
  .querySelectorAll(
    '.remark-slide-content' +
    // add additional classes to exclude here, e.g.
    // ':not(.inverse)' +
    ':not(.hide-logo)'
  )
  .forEach(el => {
    el.innerHTML += '<div class="logo"></div>';
  });
</script>

<script>
slideshow._releaseMath = function(el) {
  var i, text, code, codes = el.getElementsByTagName('code');
  for (i = 0; i < codes.length;) {
    code = codes[i];
    if (code.parentNode.tagName !== 'PRE' && code.childElementCount === 0) {
      text = code.textContent;
      if (/^\\\((.|\s)+\\\)$/.test(text) || /^\\\[(.|\s)+\\\]$/.test(text) ||
          /^\$\$(.|\s)+\$\$$/.test(text) ||
          /^\\begin\{([^}]+)\}(.|\s)+\\end\{[^}]+\}$/.test(text)) {
        code.outerHTML = code.innerHTML;  // remove <code></code>
        continue;
      }
    }
    i++;
  }
};
slideshow._releaseMath(document);
</script>
<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
(function () {
  var script = document.createElement('script');
  script.type = 'text/javascript';
  script.src  = 'https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML';
  if (location.protocol !== 'file:' && /^https?:/.test(script.src))
    script.src  = script.src.replace(/^https?:/, '');
  document.getElementsByTagName('head')[0].appendChild(script);
})();
</script>
  </body>
</html>
